These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1706136)

  • 41. [Hormonal environment and antiandrogenic treatment in benign prostatic hypertrophy].
    Katayama T; Umeda K; Kazama T
    Hinyokika Kiyo; 1986 Nov; 32(11):1584-9. PubMed ID: 2435122
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapy with progestational agents in advanced benign prostatic hypertrophy.
    Geller J; Angrist A; Nakao K; Newman H
    JAMA; 1969 Nov; 210(8):1421-7. PubMed ID: 4187537
    [No Abstract]   [Full Text] [Related]  

  • 43. Binding of chlormadinone acetate to cytosol from human benign prostatic hypertrophy.
    Kodama T; Wakisaka M; Shimazaki J
    Endocrinol Jpn; 1980 Feb; 27(1):53-7. PubMed ID: 6156069
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DIAGNOSIS AND MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA IN A PIED TAMARIN (SAGUINUS BICOLOR).
    Barbon AR; Ordóñez IA; Haworth P; Glendewar G; Routh A; Pocknell A
    J Zoo Wildl Med; 2016 Jun; 47(2):609-13. PubMed ID: 27468035
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Transrectal ultrasonography of the prostate--prolonged finger of the urologist].
    Aus G; Hugosson J
    Lakartidningen; 1992 Nov; 89(45):3827-31. PubMed ID: 1281251
    [No Abstract]   [Full Text] [Related]  

  • 46. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
    Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T
    Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of the new steroidal antiandrogen TZP-4238 on hormone-induced canine prostatic hyperplasia.
    Takezawa Y; Fukabori Y; Yamanaka H; Mieda M; Honma S; Kushitani M; Hamataki N
    Prostate; 1992; 21(4):315-29. PubMed ID: 1281324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of chlormadinone acetate (CMA), antiandrogen, on the pituitary, testis, prostate and adrenal gland of the dog with spontaneous benign prostatic hyperplasia.
    Murakoshi M; Ikeda R; Fukui N
    J Toxicol Sci; 2001 Aug; 26(3):119-27. PubMed ID: 11552295
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
    Akakura K; Furuya Y; Ito H
    Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Gestagens: a new method of hormonal therapy in benign prostatic hypertrophy].
    Vernet D
    Urol Int; 1970; 25(3):263-8. PubMed ID: 4112432
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of the steroidal androgen receptor antagonist, Win 49,596, on the prostate and testis of beagle dogs.
    Juniewicz PE; McCarthy M; Lemp BM; Barbolt TA; Shaw C; Hollenbaugh DM; Winneker RC; Reel JR; Batzold FH
    Endocrinology; 1990 May; 126(5):2625-34. PubMed ID: 1691701
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The mechanism of antiandrogenic action of chlormadinone acetate (author's transl)].
    Ito Y; Kurosawa I; Yamanaka H; Koya A; Imai K
    Nihon Hinyokika Gakkai Zasshi; 1977 Jun; 68(6):537-52. PubMed ID: 72181
    [No Abstract]   [Full Text] [Related]  

  • 53. Effects of mepartricin (S-160) on spontaneous canine benign prostatic hyperplasia.
    Yoshinaka Y; Kobayasi H; Kirihara J; Sato F; Shakutou S; Yamanaka H
    Eur Urol; 2000 Apr; 37(4):428-35. PubMed ID: 10765073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of anti-androgen (TZP-4238) on steroid-induced canine prostatic hyperplasia. Light and electron microscopic investigations.
    Murakoshi M; Inada R; Makino M; Suzuki M; Mieda M; Honma S; Yamanaka H
    Acta Pathol Jpn; 1990 Dec; 40(12):871-9. PubMed ID: 1710865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Hormonal therapy of benign prostatic hyperplasia].
    Horninger W; Bartsch G
    Urologe A; 1995 Jan; 34(1):9-15. PubMed ID: 7533450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacological treatment for common prostatic conditions in dogs - benign prostatic hyperplasia and prostatitis: an update.
    Niżański W; Levy X; Ochota M; Pasikowska J
    Reprod Domest Anim; 2014 Jun; 49 Suppl 2():8-15. PubMed ID: 24947855
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
    de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
    Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Endorectal ultrasound of the prostate].
    Chanis G; Chanis GD
    Rev Med Panama; 1993 May; 18(2):120-7. PubMed ID: 7687067
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
    Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
    Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Evaluation of weight of the prostate by transrectal longitudinal ultrasonography].
    Tanaka S; Morikawa Y
    Nihon Hinyokika Gakkai Zasshi; 1991 Jan; 82(1):67-71. PubMed ID: 1710677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.